ChristopherDavidPilcherMD
Medicine/Pediatrics • San Francisco, CAAssociate Professor, Medicine, UCSF School of Medicine
Are you Dr. Pilcher?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 37 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
995 Potrero Ave
Ward 84, Building 80
San Francisco, CA 94110Phone+1 415-476-4082Fax+1 415-476-6953
Summary
- Dr. Christopher Pilcher, MD is an internist and pediatrician in San Francisco, California. He is currently licensed to practice medicine in California. He is an Associate Professor at UCSF School of Medicine.
Education & Training
University of North Carolina HospitalsFellowship, Infectious Disease, 1997 - 2000
Duke University HospitalResidency, Internal Medicine/Pediatrics, 1993 - 1997
University of Vermont College of MedicineClass of 1993
Certifications & Licensure
CA State Medical License 2007 - 2019
Clinical Trials
Publications & Presentations
PubMed
- Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease.Alton Barbehenn, Lei Shi, Junzhe Shao, Rebecca Hoh, Heather M Hartig
Nature Communications. 2024-11-18 - 1 citationsRapid Biphasic Decay of Intact and Defective HIV DNA Reservoir During Acute Treated HIV Disease.Alton Barbehenn, Lei Shi, Junzhe Shao, Rebecca Hoh, Heather M Hartig
Medrxiv. 2024-08-22 - 1 citationsA cohort-based study of host gene expression: tumor suppressor and innate immune/inflammatory pathways associated with the HIV reservoir size.Ashok K Dwivedi, Germán G Gornalusse, David A Siegel, Alton Barbehenn, Cassandra Thanh
Plos Pathogens. 2023-11-01
Grant Support
- Targeting Acute HIVNational Institute Of Mental Health2006–2007
- Acute HIV Infection And Early Disease Research ProgramNational Center For Research Resources2006
- ACTG A5217 - Treatment VS NO Treatment In Newly Infected HIV-1 SubjectsNational Center For Research Resources2006
- Once Daily Regimen Of Didanosine, Tenofovir And EfavirenzNational Center For Research Resources2005–2006
- Three Protease Inhibitor-Sparing Regimens For The Initial Treatment Of HIVNational Center For Research Resources2004–2006
- Lamivudine PLUS Stavudine PLUS Abacavir PLUS Amprenavir/RitonaverNational Center For Research Resources2004–2006
- Targeting Acute HIVNational Institute Of Mental Health2003–2006
- Vaccine-Induced Helper &Ctl Responses To Control Viremia In The Absense Of ARTNational Center For Research Resources2004–2005
- Immunologic And Virologic Indices In Two Age-Differentiated Cohorts Of HIVNational Center For Research Resources2004–2005
- Haart-Induced Immune Restoration With The Use Of CyclosporineNational Center For Research Resources2004–2005
- Restarting Therapy With Potent Antiretroviral Therapy +/- Interleukin-2National Center For Research Resources2004
- Augmentation Of Hiv-Specific Helper And CTL ResponsesNational Center For Research Resources2004
- Cytoreductive Chemotherapy Targeting HIV ReservoirsNational Institute Of Allergy And Infectious Diseases2000–2004
- Antiviral Activity Of T-1249 In HIV-1 Infected AdultsNational Center For Research Resources2000
